Rakovina Therapeutics Reports Q1 Results with Increased R&D Expenses and Improved Cash Position
Rakovina Therapeutics (RKV:CA) reported a net loss of $1.68 million for the first quarter of 2026, compared to a larger loss in the same period last year. The company's cash reserves increased significantly from $298,758 at the end of December 2025 to $585,908 as of March 31, 2026.
